Xtant Medical

Xtant Medical is dedicated to the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal fixation systems. The company offers innovative orthobiologic products, including synthetic grafts, demineralized bone matrix (DBM), placental tissue matrix, viable cell allografts, soft tissue allografts, and traditional allografts, all designed and manufactured in a state-of-the-art tissue processing facility. Xtant Medical also provides a range of spinal implant systems for cervical, thoraco-lumbar, and interbody procedures, addressing complex, deformity, and degenerative conditions. In addition to its orthobiologic products, the company offers fixation products for cervical, thoracolumbar, and sacroiliac joints. In April 2024, Xtant Medical launched SimpliGraft™ and SimpliMax™ for chronic and acute wounds. The company reported a 55% revenue growth in the first quarter of 2024 and raised its full-year revenue guidance. Xtant Medical’s corporate offices are located at 664 Cruiser Lane, Belgrade, MT 59714. The company increased its revolving credit facility to $17 million with MidCap Financial in March 2024 and announced record full-year 2023 revenue of $91.3 million. In October 2023, Xtant Medical acquired nanOss production operations from RTI Surgical. The company highlighted its growing product portfolio at NASS 2023 and provides quick access to product literature and professional education resources online. Xtant Medical is committed to improving the quality of life for patients by designing, manufacturing, and distributing safe and effective medical devices and human tissues for transplant.